Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
NCT ID: NCT03833154
Last Updated: 2025-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
724 participants
INTERVENTIONAL
2019-03-06
2028-04-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
An additional cohort will assess Osimertinib following SBRT in patients with early stage unresected T1 to T3N0M0 NSCLC harbouring an EGFR mutation.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary objective of main cohort is to assess the efficacy of Durvalumab with SoC SBRT compared to placebo with SoC SBRT in terms of PFS. Key secondary is to assess the efficacy of Durvalumab with SoC SBRT compared to placebo with SoC SBRT in terms of Overall Survival (OS).
In addition, a study cohort with a sufficient number of patients harboring an EGFR-TKI sensitizing mutation, will receive Osimertinib treatment after completion of SoC SBRT as definitive treatment of Stage I/II lymph node-negative NSCLC. The primary objective of Osimertinib cohort is to assess efficacy of Osimertinib following SoC SBRT in terms of 4-year PFS. Key secondary objectives include safety, OS and efficacy of Osimertininb treatment with SBRT.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SoC SBRT + Durvalumab Therapy (Main Cohort)
SBRT
Durvalumab (PD-L1 monoclonal antibody) 1500 mg every 4 weeks \[q4w\] intravenously \[iv\] for up to 26 cycles or until progression or other discontinuation criteria are met.
Durvalumab
Durvalumab 1500 mg every 4 weeks \[q4w\] intravenously \[iv\] for up to 26 cycles or until progression or other discontinuation criteria are met.
SoC SBRT + Placebo Therapy (Main Cohort)
SBRT
Placebo (matching placebo for infusion) every 4 weeks iv for up to 26 cycles or until progression or other discontinuation criteria are met.
Placebo
Matching placebo for infusion every 4 weeks iv for up to 26 cycles or until progression or other discontinuation criteria are met.
SoC SBRT + Osimertinib Therapy (Osimertinib cohort, single-arm, open-label separate cohort)
SBRT
Osimertinib 80mg every day \[qd\] for oral administration up to 36 months or until progression. Osimertinib treatment should start within 7 to 14 days after completion of SBRT
(Osimertinib cohort, single-arm, open-label separate cohort)
Osimertinib 80 mg every day \[qd\] orally for up to 36 months or until progression or other discontinuation criteria are met. Osimertinib treatment should start from 7 to 14 days after completion of SBRT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Durvalumab
Durvalumab 1500 mg every 4 weeks \[q4w\] intravenously \[iv\] for up to 26 cycles or until progression or other discontinuation criteria are met.
Placebo
Matching placebo for infusion every 4 weeks iv for up to 26 cycles or until progression or other discontinuation criteria are met.
(Osimertinib cohort, single-arm, open-label separate cohort)
Osimertinib 80 mg every day \[qd\] orally for up to 36 months or until progression or other discontinuation criteria are met. Osimertinib treatment should start from 7 to 14 days after completion of SBRT
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Planned SoC SBRT as definitive treatment
3. World Health Organization (WHO)/ECOG PS of 0, 1 or 2
4. Life expectancy of at least 12 weeks
5. Body weight \>30 kg
6. Submission of tumor tissue sample if available
7. Adequate organ and marrow function required
8. Patients with central or peripheral lesions are eligible
9. Staging studies must be done during screening (PET-CT within 10 weeks)
10. Patients with a history of metachronous NSCLC and synchronous lesions are eligible with some exceptions
1. Age ≥18 years
2. Planned SoC SBRT as definitive treatment
3. WHO/ECOG PS of 0, 1, or 2
4. Patients with central or peripheral lesions are eligible
5. Patients with a history of metachronous NSCLC and synchronous lesions are eligible with some exceptions
6. Staging studies must be done during screening (PET-CT within 10 weeks)
7. Submission of tumor tissue sample if available
8. Confirmation by local laboratory that the tumor harbors one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R)
9. Adequate bone marrow reserve or organ function required
10. Female patients should be using highly effective contraceptive measures
11. Male patients should be asked to use barrier contraceptives (ie, condoms) during sex with all partners during the trial and avoid procreation
Exclusion Criteria
2. History of allogeneic organ transplantation
3. History of another primary malignancy with exceptions
4. History of active primary immunodeficiency
5. Epidermal growth factor receptor local testing is strongly recommended prior to enrollment. Patients with a tumor harboring an EGFRm per local testing will be excluded from the main cohort
6. Prior exposure to immune-mediated therapy with exceptions
1. Mixed small cell and non-small cell cancer
2. Patients with known or increased risk factor for QTc prolongation
3. Treatment with any of the following:
* Preoperative or adjuvant platinum-based or other chemotherapy for the disease under investigation
* Prior treatment with neoadjuvant or adjuvant EGFR TKI
* Patients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inducers of CYP3A4
4. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of osimertinib
5. Any of the following cardiac criteria
* Mean resting corrected QT interval \>470 msec, obtained from 3 ECGs
* Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG.
* Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, or unexplained -sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval
* Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD
18 Years
130 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Tuscaloosa, Alabama, United States
Research Site
Chandler, Arizona, United States
Research Site
Phoenix, Arizona, United States
Research Site
Tucson, Arizona, United States
Research Site
Duarte, California, United States
Research Site
Long Beach, California, United States
Research Site
Los Angeles, California, United States
Research Site
San Diego, California, United States
Research Site
Newark, Delaware, United States
Research Site
Washington D.C., District of Columbia, United States
Research Site
Bay Pines, Florida, United States
Research Site
Jacksonville, Florida, United States
Research Site
Miami Beach, Florida, United States
Research Site
Orlando, Florida, United States
Research Site
Atlanta, Georgia, United States
Research Site
Atlanta, Georgia, United States
Research Site
Chicago, Illinois, United States
Research Site
Chicago, Illinois, United States
Research Site
Chicago, Illinois, United States
Research Site
Decatur, Illinois, United States
Research Site
Elmhurst, Illinois, United States
Research Site
Naperville, Illinois, United States
Research Site
Fort Wayne, Indiana, United States
Research Site
Cedar Rapids, Iowa, United States
Research Site
Iowa City, Iowa, United States
Research Site
Elizabethtown, Kentucky, United States
Research Site
Lexington, Kentucky, United States
Research Site
Louisville, Kentucky, United States
Research Site
Metairie, Louisiana, United States
Research Site
New Orleans, Louisiana, United States
Research Site
South Portland, Maine, United States
Research Site
Annapolis, Maryland, United States
Research Site
Baltimore, Maryland, United States
Research Site
Rosedale, Maryland, United States
Research Site
Silver Spring, Maryland, United States
Research Site
Towson, Maryland, United States
Research Site
Boston, Massachusetts, United States
Research Site
Ann Arbor, Michigan, United States
Research Site
Detroit, Michigan, United States
Research Site
Royal Oak, Michigan, United States
Research Site
Duluth, Minnesota, United States
Research Site
Rochester, Minnesota, United States
Research Site
St Louis, Missouri, United States
Research Site
Omaha, Nebraska, United States
Research Site
Las Vegas, Nevada, United States
Research Site
Lebanon, New Hampshire, United States
Research Site
Camden, New Jersey, United States
Research Site
Paramus, New Jersey, United States
Research Site
Albany, New York, United States
Research Site
East Syracuse, New York, United States
Research Site
New Hyde Park, New York, United States
Research Site
New York, New York, United States
Research Site
Rochester, New York, United States
Research Site
Stony Brook, New York, United States
Research Site
Syracuse, New York, United States
Research Site
The Bronx, New York, United States
Research Site
The Bronx, New York, United States
Research Site
Winston-Salem, North Carolina, United States
Research Site
Grand Forks, North Dakota, United States
Research Site
Akron, Ohio, United States
Research Site
Cincinnati, Ohio, United States
Research Site
Cincinnati, Ohio, United States
Research Site
Cleveland, Ohio, United States
Research Site
Portland, Oregon, United States
Research Site
Portland, Oregon, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
Charleston, South Carolina, United States
Research Site
Sioux Falls, South Dakota, United States
Research Site
Watertown, South Dakota, United States
Research Site
Austin, Texas, United States
Research Site
Dallas, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Sherman, Texas, United States
Research Site
Burlington, Vermont, United States
Research Site
Richmond, Virginia, United States
Research Site
Bellingham, Washington, United States
Research Site
Seattle, Washington, United States
Research Site
Spokane Valley, Washington, United States
Research Site
Milwaukee, Wisconsin, United States
Research Site
Clayton, , Australia
Research Site
Aalst, , Belgium
Research Site
Charleroi, , Belgium
Research Site
Edegem, , Belgium
Research Site
Ghent, , Belgium
Research Site
Leuven, , Belgium
Research Site
Barretos, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Recife, , Brazil
Research Site
Rio de Janeiro, , Brazil
Research Site
São Paulo, , Brazil
Research Site
Volta Redonda, , Brazil
Research Site
Edmonton, Alberta, Canada
Research Site
London, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Changchun, , China
Research Site
Changsha, , China
Research Site
Chengdu, , China
Research Site
Fuzhou, , China
Research Site
Hangzhou, , China
Research Site
Hangzhou, , China
Research Site
Hefei, , China
Research Site
Jinan, , China
Research Site
Nanjing, , China
Research Site
Shanghai, , China
Research Site
Shanghai, , China
Research Site
Shanghai, , China
Research Site
Shanghai, , China
Research Site
Shenyang, , China
Research Site
Suzhou, , China
Research Site
Wenzhou, , China
Research Site
Wuhan, , China
Research Site
Wuhan, , China
Research Site
Zhengzhou, , China
Research Site
Bron, , France
Research Site
Dijon, , France
Research Site
Lyon, , France
Research Site
Nantes, , France
Research Site
Pierre-Bénite, , France
Research Site
Toulouse, , France
Research Site
Villejuif, , France
Research Site
Dresden, , Germany
Research Site
Göttingen, , Germany
Research Site
Halle, , Germany
Research Site
Hanover, , Germany
Research Site
Heidelberg, , Germany
Research Site
Homburg, , Germany
Research Site
Regensburg, , Germany
Research Site
Trier, , Germany
Research Site
Athens, , Greece
Research Site
Athens, , Greece
Research Site
Thessaloniki, , Greece
Research Site
Haifa, , Israel
Research Site
Jerusalem, , Israel
Research Site
Kfar Saba, , Israel
Research Site
Petah Tikva, , Israel
Research Site
Ramat Gan, , Israel
Research Site
Tel Aviv, , Israel
Research Site
Florence, , Italy
Research Site
Genova, , Italy
Research Site
Milan, , Italy
Research Site
Orbassano, , Italy
Research Site
Padua, , Italy
Research Site
Pavia, , Italy
Research Site
Roma, , Italy
Research Site
Rozzano, , Italy
Research Site
Akashi-shi, , Japan
Research Site
Bunkyō City, , Japan
Research Site
Chūōku, , Japan
Research Site
Fukuoka, , Japan
Research Site
Hirosaki-shi, , Japan
Research Site
Hiroshima, , Japan
Research Site
Kobe, , Japan
Research Site
Niigata, , Japan
Research Site
Osaka, , Japan
Research Site
Sakaishi, , Japan
Research Site
Sapporo, , Japan
Research Site
Sunto-gun, , Japan
Research Site
Toyoake-shi, , Japan
Research Site
Yokohama, , Japan
Research Site
Amsterdam, , Netherlands
Research Site
Groningen, , Netherlands
Research Site
Utrecht, , Netherlands
Research Site
Bydgoszcz, , Poland
Research Site
Elblag, , Poland
Research Site
Gdansk, , Poland
Research Site
Katowice, , Poland
Research Site
Lodz, , Poland
Research Site
Warsaw, , Poland
Research Site
Hato Rey, , Puerto Rico
Research Site
Kazan, Tatarstan, , Russia
Research Site
Moscow, , Russia
Research Site
Moscow, , Russia
Research Site
Moscow, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Ufa, , Russia
Research Site
Yekaterinburg, , Russia
Research Site
Cheongju-si, , South Korea
Research Site
Goyang-si, , South Korea
Research Site
Gyeonggi-do, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Badajoz, , Spain
Research Site
Barcelona, , Spain
Research Site
L'Hospitalet de Llobregat, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Málaga, , Spain
Research Site
San Sebastián, , Spain
Research Site
Santiago de Compostela, , Spain
Research Site
Seville, , Spain
Research Site
Valencia, , Spain
Research Site
Zaragoza, , Spain
Research Site
Ankara, , Turkey (Türkiye)
Research Site
Ankara, , Turkey (Türkiye)
Research Site
Istanbul, , Turkey (Türkiye)
Research Site
Izmir, , Turkey (Türkiye)
Research Site
Kocaeli, , Turkey (Türkiye)
Research Site
Birmingham, , United Kingdom
Research Site
Leeds, , United Kingdom
Research Site
London, , United Kingdom
Research Site
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Lung Cancer Study Locator details (for US)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-002572-41
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
D9103C00001
Identifier Type: -
Identifier Source: org_study_id